An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).
Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either:
Inclusion Criteria:
Histologically and/or cytologically confirmed adenocarcinoma of the colon or rectum which is locally advanced unresectable or metastatic
Able to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides) obtained prior to treatment initiation to a central laboratory
HER2+ disease as determined by a tissue based assay performed at a central laboratory.
Participant has rat sarcoma viral oncogene homolog wild-type (RAS WT) disease as determined by local or central testing. For central RAS analysis, tissue sample must be analyzed within 1 year of biopsy date.
Radiographically measurable disease per RECIST v1.1 with:
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
CNS Inclusion - based on contrast brain magnetic resonance imaging, participants may have any of the following:
Exclusion Criteria:
Prior systemic anticancer therapy for colorectal cancer (CRC) in the locally advanced unresectable or metastatic setting; note that participants may have received a maximum of 2 doses of mFOLFOX6 in the locally advanced/unresectable or metastatic setting prior to randomization.
Radiation therapy within 14 days prior to enrollment (or within 7 days in the setting of stereotactic radiosurgery)
Previous treatment with anti-HER2 therapy
Ongoing Grade 3 or higher neuropathy
Active or untreated gastrointestinal (GI) perforation at the time of screening.
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Anaheim, California 92806, United States
Baldwin Park, California 91706, United States
Bellflower, California 90706, United States
Fontana, California 92335, United States
Fountain Valley, California 92708, United States
Harbor City, California 90710, United States
Irvine, California 92618, United States
Los Angeles, California 90027, United States
Los Angeles, California 90034, United States
Newport Beach, California 92663, United States
Ontario, California 91761, United States
Panorama City, California 91402, United States
Riverside, California 92505, United States
San Diego, California 92108, United States
San Diego, California 92120, United States
San Marcos, California 92078, United States
Woodland Hills, California 91367, United States
Louisville, Kentucky 40241, United States
Minneapolis, Minnesota 55404, United States
Saint Louis Park, Minnesota 55416, United States
Woodbury, Minnesota 55125, United States
New York, New York 10065, United States
Durham, North Carolina 27710, United States
Oregon City, Oregon 97045, United States
Portland, Oregon 97225, United States
Portland, Oregon 97225, United States
Butler, Pennsylvania 16001, United States
Greensburg, Pennsylvania 15601, United States
Harrisburg, Pennsylvania 17109, United States
Irwin, Pennsylvania 15642, United States
Mechanicsburg, Pennsylvania 17050, United States
Blacksburg, Virginia 24060, United States
Low Moor, Virginia 24457, United States
Roanoke, Virginia 24014, United States
Salem, Virginia 24153, United States
Wytheville, Virginia 24382, United States
Rosario, Santa Fe Province S2000DEJ, Argentina
CABA, 1280, Argentina
Córdoba, X5001 HWE, Argentina
Barra da Tijuca, Rio de Janeiro 22.775-001, Brazil
Rio de Janeiro, Rio de Janeiro 22775-001, Brazil
Rio de Janeiro, Rio de Janeiro 22793-080, Brazil
Porto Alegre, Rio Grande do Sul 91350-200, Brazil
Jaú, São Paulo 17210-120, Brazil
Santo André, São Paulo 09060-650, Brazil
São José do Rio Preto, São Paulo CEP 15090-000, Brazil
São Paulo, 01245-000, Brazil
Guangzhou, Guangdong 510655, China
Haikou, Hainan 570216, China
Changsha, Hunan 410011, China
Suzhou, Jiangsu 215031, China
Nanchang, Jiangxi 330006, China
Jinzhou, Liaoning 121001, China
Shanghai, Shanghai Municipality 200092, China
Hangzhou, Zhejiang 310009, China
Hangzhou, Zhejiang 310016, China
Chongqing, 400042, China
Besançon, Other 25000, France
Saint-Priest-en-Jarez, 42270, France
Berlin, 13353, Germany
Dresden, 01307, Germany
Heraklion, Crete 71500, Greece
Nea Efkarpia, Thessaloniki 56403, Greece
Monserrato, Cagliari 09042, Italy
Avellino, Campania 83100, Italy
Milan, Lombardy 20162, Italy
Verona, Other 37134, Italy
Catania, Sicily 95122, Italy
Foggia, 71122, Italy
Sondrio, 23100, Italy
Verona, 37134, Italy
Kashiwa-shi, Chiba 277-8577, Japan
Kobe, Hyōgo 650-0047, Japan
Kita-gun, Kagawa-ken 761-0793, Japan
Kawasaki-shi, Kanagawa 216-8511, Japan
Osakasayama-shi, Osaka 589-8511, Japan
Takatsuki-shi, Osaka 569-8686, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Koto-ku, Tokyo 135-8550, Japan
Konin, Greater Poland Voivodeship 62-500, Poland
Warsaw, Masovian Voivodeship 02-034, Poland
Warsaw, Masovian Voivodeship 02-781, Poland
Warsaw, Masovian Voivodeship 04-141, Poland
Rzeszów, Podkarpackie Voivodeship 35-021, Poland
Gdansk, Pomeranian Voivodeship 80-214, Poland
Gdansk, Pomeranian Voivodeship 80-214, Poland
L'Hospitalet de Llobregat, Barcelona 08908, Spain
San Cristóbal de La Laguna, Santa CRUZ DE Tenerife 38320, Spain
Barcelona, 08035, Spain
Zurich, 8091, Switzerland
Newcastle upon Tyne, Chelsea NE7 7DN, United Kingdom
Glasgow, Glasgow CITY G12 0YN, United Kingdom
Bristol, BS2 8ED, United Kingdom
Cambridge, CB2 0QQ, United Kingdom
Leeds, LS97TF, United Kingdom